Intracellular Therapies
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 22.5m | 81.7m | 249m | 462m | 668m | 917m | 1.4b |
| % growth | 37071 % | 263 % | 205 % | 86 % | 44 % | 37 % | 48 % |
| EBITDA | (231m) | (286m) | (264m) | (159m) | (104m) | 7.0m | 306m |
| % EBITDA margin | (1026 %) | (350 %) | (106 %) | (34 %) | (16 %) | 1 % | 23 % |
| Profit | (227m) | (284m) | (256m) | (140m) | (64.2m) | 71.9m | 393m |
| % profit margin | (1008 %) | (348 %) | (103 %) | (30 %) | (10 %) | 8 % | 29 % |
| EV / revenue | 84.0x | 47.1x | 17.7x | 13.8x | 10.3x | 7.5x | 4.8x |
| EV / EBITDA | -8.2x | -13.5x | -16.8x | -40.2x | -66.0x | 985.9x | 21.1x |
| R&D budget | 65.8m | 88.8m | 135m | 180m | - | - | - |
| R&D % of revenue | 292 % | 109 % | 54 % | 39 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.9m | Series A | ||
$7.9m | Series B | ||
$730k | Grant | ||
$8.0m | Series C | ||
| N/A | $5.3m | Series C | |
| N/A | $15.3m | Debt | |
| N/A | $60.0m | Secondary | |
| N/A | N/A | IPO | |
* | N/A | $121m | Post IPO Equity |
* | N/A | $327m | Post IPO Equity |
$348k | Grant | ||
* | N/A | $150m | Post IPO Equity |
| N/A | $2.9m | Grant | |
* | N/A | $295m | Post IPO Equity |
* | N/A | $350m | Post IPO Equity |
* | N/A | $460m | Post IPO Equity |
* | N/A | $500m | Post IPO Equity |
| Total Funding | AUD43.5m | ||
Related Content
Recent News about Intracellular Therapies
EditIntra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and neurologic disorders. The company operates in the healthcare sector, targeting patients suffering from conditions such as schizophrenia and bipolar depression. Its flagship product, CAPLYTA, is an FDA-approved medication designed to address these mental health issues. The company serves healthcare providers, patients, and caregivers, aiming to improve the quality of life for individuals affected by these disorders.
Intra-Cellular Therapies employs a business model centered around the discovery, development, and commercialization of novel therapeutics. Revenue is primarily generated through the sale of CAPLYTA and other investigational compounds in their pipeline. The company leverages its extensive expertise in drug development to bring new treatments from the research phase to market readiness.
Key markets include the United States and other regions with significant demand for advanced neuropsychiatric treatments. The company continuously invests in research and development to expand its portfolio and address unmet medical needs.
Keywords: neuropsychiatric, neurologic, disorders, CAPLYTA, biopharmaceutical, FDA-approved, schizophrenia, bipolar depression, healthcare, innovation.